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Abstract (250 words max) 
 
Background: The diagnosis of occupational asthma (OA) can be challenging and 
needs a stepwise approach. However, the predictive value of the methacholine 
challenge has never been addressed specifically in this context. 
Objective: To evaluate the sensitivity, specificity, and positive and negative predictive 
values of the methacholine challenge in OA. 
Methods: A Canadian database was used to review 1012 cases of workers referred for 
a suspicion of OA between 1983 and 2011 and having had a specific inhalation 
challenge (SIC). We calculated the sensitivity, specificity, and positive and negative 
predictive values of methacholine challenges at baseline of the SIC, at the workplace, 
and outside work. 
Results: At baseline, the methacholine challenge showed an overall sensitivity of 80.2% 
and a specificity of 47.1%, with positive and negative predictive values of 36.5% and 
86.3%, respectively. Among the 430 subjects who were still working, the baseline 
measures displayed a sensitivity of 95.4%, a specificity of 40.1%, and positive and 
negative predictive values of 41.1% and 95.2%, respectively. Among the 582 subjects 
tested outside work, the baseline measures demonstrated a sensitivity and specificity of 
66.7% and 52%, respectively, and positive and negative predictive values of 31.9% and 
82.2%, respectively. When considering all subjects tested by a methacholine challenge 
at least once while at work (479), the sensitivity, specificity, and positive and negative  
predictive values were 98.1%, 39.1%, 44.0% and 97.7%, respectively.   
Conclusion: A negative methacholine challenge in a patient still exposed to the 
causative agent at work makes the diagnosis of OA very unlikely.  3  
 Clinical implications   
A negative methacholine challenge in a subject still exposed to the causative agent at 
work makes the diagnosis of OA very unlikely.   
Capsule summary 
 
This is the first report confirming that the methacholine challenge is a useful tool for 
clinicians to predict the response to a SIC in workers with a suspicion of OA.  
  
Key words: bronchial responsiveness; methacholine challenge; occupational asthma   
Abbreviations used 
 
OA:  Occupational asthma 
ACCP: American College of Chest Physicians  
NSBR: Nonspecific bronchial responsiveness  
SIC:  Specific inhalation challenge  
CI:  Confidence interval 
NPV:  Negative predictive value 
PPV:  Positive predictive value 
IQR:  Interquartile range  
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INTRODUCTION 
The diagnosis of occupational asthma (OA) can be challenging and needs a stepwise 
approach, as stated in a consensus published by the American College of Chest 
Physicians (ACCP) (1). One step of this approach consists in confirming the diagnosis of 
asthma by objective means, i.e. demonstration of reversible airflow obstruction or 
increased non specific bronchial responsiveness (NSBR) in subjects without airflow 
limitation (2). Indeed, a negative methacholine challenge (PC20 > 16 mg/ml) allows to 
exclude current asthma with a reasonable confidence in symptomatic subjects(3) 
However, several studies have shown that subjects with OA may have a normal NSBR 
when away from work and asymptomatic.(4-6) 
A systematic review has reported the pooled estimates for the sensitivity and 
specificity of NSBR compared to the specific inhalation challenge (SIC) regarding both 
high and low molecular weight agents. The sensitivity and specificity for high molecular 
weight agents were 79.3% (95% confidence interval [CI]: 67.7-87.6%) and 51.3% (95% 
CI: 35.2-67.2%), respectively, and 66.7% (95% CI: 58.4-74.0%) and 63.9% (95% CI: 
56.1-71.0%), respectively, for low molecular weight agents. (7). To improve the 
diagnostic accuracy in assessing NSBR, several authors have proposed to monitor PC20 
at and off work.(8) 
The latest ACCP guidelines on work-related asthma state: “the absence of airway 
hyperresponsiveness on challenge testing has a fairly high negative predictive value 
(NPV) for current symptomatic asthma, and generally can be used to rule out active 
disease”.(1) However, to our knowledge, this statement has not been verified in a large 
study designed to assess the predictive value of the methacholine challenge in the 
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diagnosis workup of OA, either at the time of the SIC or at any time during the 
investigation. The first objective of our study was to evaluate the sensitivity, specificity, 
and NPV and positive predictive values (PPV) of methacholine challenges for the 
diagnosis of OA in workers with a suspicion of OA. The second aim was to characterize 
the cases with OA showing normal airway responsiveness before and after the SIC. 
  
METHODS 
Study design and subjects 
We performed a retrospective review of the database of workers referred to the Hôpital 
du Sacré-Coeur, Montreal, Canada, between 1983 and 2011 for a suspicion of OA. We 
included all cases of workers who had a SIC and a methacholine challenge on the 
control day (baseline) and on the last (or following) day of exposure. Procedures are 
explained in the next paragraph. We had also access to data regarding the monitoring of 
peak expiratory flows, sputum induction and the methacholine challenge when the 
challenge test was performed prior to the SIC. Data on working status were available at 
the time of the SIC. However, the database did not allow to determine if subjects were 
still exposed to the causative agents while at work, as they might have been moved to 
another location in the workplace away from exposure. The charts of workers with OA 
and normal bronchial responsiveness while working or before and after the SIC were 
reviewed by one of the authors (A.C.) to determine if they were exposed or not to the 
causative agent.  
 
Procedures 
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SICs are considered as the reference standard for diagnosing OA(1, 9) and were 
performed according to standardized methods.(10) In brief, each subject underwent a 
first day of testing during which he/she was exposed to a control product. Spirometry 
was performed before and serially for 8 h after exposure. A methacholine challenge was 
performed at the end of that day. During the following days, the subject was exposed to 
the suspected causative occupational agent, either in the laboratory or at the 
workplace(11) if the exposure could not be reproduced in the laboratory. A second 
methacholine challenge was performed on the last day or on the day following the end  
of the SIC in all subjects. OA was defined by a > 20% fall in FEV1 greater than during 
the control exposure. Spirometry was performed according to the American Thoracic 
Society/European Respiratory Society recommendations.(12) Airflow obstruction was 
defined by a FEV1/FVC ratio < 0.7.(13) Prior to the challenge, patients were asked to 
withdraw medication that could affect the bronchial response (according to their 
durations of action) except for inhaled corticosteroids which were continued at the same 
dosage but taken in the evening of each test day (9), to refrain smoking and to avoid 
foods like coffee, tea, cola drinks and chocolate. 
Methacholine challenge testing was performed according to the American 
Thoracic Society guidelines(14). Increasing serial doses of methacholine were 
administered until a > 20% FEV1 decrease or completion of the protocol (highest 
concentration of methacholine [128 mg/ml] reached). The presence of NSBR was 
defined as a provocative concentration of methacholine that induced a 20% fall in FEV1 
(or PC20) < 16 mg/ml (corresponding to a cumulative dose of 960 ug of methacholine). 
We chose a cut point of 16 mg/ml due to its higher NPV compared to 8 mg/ml.(3) Since 
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1998, sputum induction has been obtained in most subjects according to the method of 
Pin et al(15) and processed as previously described.(16) 
Subjects underwent skin prick tests with common aeroallergens and, when possible, 
with specific workplace allergens. Atopy was defined by at least one positive skin prick 
test (wheal diameter > 3 mm) (17). 
All the procedures remain sufficiently similar during the whole period to be compared. 
 
Statistical analyses 
All statistical analyses were performed with SPSS 19.0 for Mac OS X (Statistical 
Products and Service Solution, Inc., Chicago, IL). 
 
The demographic and clinical characteristics of the study population are 
expressed as the mean and standard deviation, except for data with non-normal 
distribution, expressed as the median and interquartile range (IQR). Sensitivity, 
specificity, and the relevant PPV and NPV of the methacholine challenge were 
calculated in distinct situations, ie, on the control day of SICs (baseline) for all subjects 
and, when available, while at work and off work. We used logistic regression analysis to 
evaluate the best predictors of the presence of NSBR among subjects with OA. We 
describe also a subgroup of subjects with OA, but with normal NSBR both at baseline 
and following a positive SIC, and compared them to other subjects with OA using a 
Pearson’s chi-square test to compare percentages, an ANOVA test to compare means, 
and a Mann-Whitney test to compare medians.  
 
Ethics 8  
The study was approved by the institutional research ethics committee of the Hôpital du 
Sacré-Coeur, Montreal, Canada. 
 
RESULTS 
Population characteristics 
The charts of 1012 subjects were reviewed. Table 1 shows the baseline characteristics 
of these cases. A diagnosis of OA was confirmed by a SIC in 278 (27.5%) cases. For all 
subjects, the median exposure duration was 7 years, the median symptom duration, 1 
year, and the median delay between exposure cessation to the causative agent and 
testing, 2 months. Nineteen percent of subjects had airway obstruction and 60% showed 
increased NSBR at baseline. Thirty percent of subjects were exposed to high molecular 
weight agents. Among the study population, 430 (42.5 %) were still at work when tested 
by the SIC (Table 2). 
 
Sensitivity, specificity and predictive values of the methacholine challenge 
The performance of the methacholine challenge in the situations described above is 
shown in Table 2. At SIC baseline, the methacholine challenge showed a sensitivity of 
80.2% and a specificity of 47.1%, with a PPV and NPV of 36.5% and 86.3%, 
respectively. When considering only the 430 subjects who were still working (and in 
theory exposed – this was confirmed in the 6 workers with OA and a negative PC20) at 
the time of the SIC, the baseline methacholine challenge displayed a sensitivity of 
95.4%, a specificity of 40.1%, and a PPV and a NPV of 41.1% and 95.2% respectively. 
Among the 582 subjects who had stopped working or had been relocated away from 
exposure at the time of the SIC with a median interval (minimum-maximum) between 9  
exposure cessation and SIC of 5 months (0.5-127), the baseline methacholine challenge 
demonstrated a sensitivity and a specificity of 66.7% and 52%, respectively, with a PPV 
and NPV of 31.9% and 82.2%, respectively. When considering all subjects tested by a 
methacholine challenge at least once while at work (479 subjects), the sensitivity, 
specificity, PPV and NPV of the methacholine challenge were 98.1%, 39.1%, 44.0% and 
97.7%, respectively (Table 2). Stratification for atopy did not add any precision (data not 
shown). For the type of agent (high vs low molecular weight) and considering only the 
NPV, the results are the following: for HMW agents, at SIC baseline, the NPV is 73.6% 
and increases to 96.9% when considering subjects tested by a methacholine challenge 
at least once while at work; for LMW agents, at SIC baseline, the NPV is 90.5% and 
increases to 95.9% when considering subjects tested by a methacholine challenge at 
least once while at work (data not shown).  
Logistic regression analysis showed that, inhaled corticosteroid use, FEV1, 
FEV1/FVC < 0.7, and being still at work at baseline were significant independent 
predictors for the presence of increased NSBR at baseline among the 278 subjects with 
OA (Table 3) with odds ratios (OR) of 2.7 (95% CI: 1.2-5.9), 0.6 (95% CI: 0.3-1.0), 0.2 
(95% CI: 0.0-1.0), and 6.2 (95% CI: 2.7-14.4),  respectively. 
 
Subjects without NSBR before and after SIC 
Among the 278 subjects with OA, 23 showed no increased NSBR both at baseline and 
post-SIC (Table 4). These subjects received less frequently inhaled corticosteroids, had 
less often airway obstruction, and were less often working at the baseline SIC compared 
to other cases with OA (P value < 0.05).  However, among these 23 subjects, 11 had an 
increased NSBR on at least one occasion before the SIC testing while exposed at work. 10  
Among the remaining 12 subjects with a PC20 > 16mg/ml ever, none had a methacholine 
challenge while still exposed to the causal agent at work. Fourteen of the 23 subjects 
had sputum induction performed before and after the SIC (data not shown): 3 were 
unable to produce sputum and 10/11 showed an increase in the eosinophil count post-
SIC (median increase in eosinophil count, 6.5%; IQR: 41.2%). Nine of the 23 subjects 
(39.1%) were exposed to flour. 
 
DISCUSSION 
To our knowledge, this is the first study demonstrating the usefulness of the 
methacholine challenge to predict the response to a SIC in a large sample of workers 
with a suspicion of OA and using the SIC as the reference standard for its diagnosis. 
The results confirm two recommendations published by the ACCP.(1) First, a negative 
methacholine challenge when the subject is at work makes the diagnosis of OA highly 
unlikely since the negative predictive value of the test in this population is 95.2%. 
Second, it emphasizes the importance of performing the diagnosis work-up when the 
subject is still at work as the NPV of the baseline methacholine response at the time of 
the SIC improves from 82.2% when he/she is off work to 95.2% at work. This NPV 
increased to 97.7% when considering workers tested by a methacholine challenge at 
least once when still at work (including those at work during the baseline methacholine 
challenge and those off work during the baseline methacholine challenge, but with a 
previous challenge when at work).  
The value of performing methacholine challenge testing while at work is 
confirmed in the multivariable analysis in which the best predictor for the presence of 
increased NSBR is being at work at the time of the SIC (OR: 6.2; 95% CI: 2.7-14.4). 11  
Among the other predictors, the use of inhaled corticosteroids, the level of baseline 
FEV1 and the presence of airway obstruction are consistent with the fact that these 
parameters are associated with the presence of asthma.  Another important point is the 
repetition of methacholine challenges over time in subjects at work. In those with one 
negative methacholine response while at work, increasing the number of methacholine 
challenges may improve the NPV of the test by reducing false-negative results. The 
latter may be explained by several reasons: technical error; medication taken 
inadvertently; no exposure for several days to the causative agent,  with less than a 
week being enough to normalize NSBR.(18) However, we cannot give a precise 
response, eg, the number of methacholine challenges needed, as the database lacked 
this information. 
  Most workers with OA showed bronchial hyperresponsiveness either before or at least 
after the SIC. However, 23 workers with a diagnosis of OA had a NSBR in the normal range 
(PC20>16 mg/ml)  both at baseline and post-SIC. This is likely explained by the fact that their 
NSBR disappeared following cessation of exposure. Most who had sputum induction (10/11) 
showed evidence of eosinophilic airway inflammation following the SIC. Indeed, Lemiere at al. 
have shown that bronchial eosinophilia may precede changes in bronchial responsiveness 
after a SIC.(19) Furthermore, 11/23 subjects had at least one positive methacholine challenge 
before SIC testing, while none of the remaining subjects had a methacholine challenge 
performed when still exposed to the causative agent. This supports the value of monitoring 
PC20 while at work, which may improve its NPV.  
          The limitations of our study are the lack of data related to the symptoms of most workers 
and their real exposure at the time of the methacholine challenge. The strengths of the study 
are the large sample size and the use of the reference standard challenge (SIC) to diagnose 12  
OA.  
These data demonstrate that the methacholine challenge has a high NPV for 
excluding the diagnosis of OA in a worker still at work, using a CP20 > 16mg/ml as the 
cut-off point of normality. However, there is still a place for clinical judgment, coupled 
with the monitoring of peak expiratory flows and, if possible, sputum induction, to decide 
if there is still a need to perform a SIC, which remains the reference standard, in these 
patients. Whenever possible, the diagnostic work-up of workers, including methacholine 
challenges, should be done while the patient is still exposed at work.  
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 TABLE 1. Study population  
 
 
 
OA: occupational asthma; NSBHR: nonspecific bronchial hyperresponsiveness; NS: not significant; ICS: 
inhaled corticosteroids; SPT: skin prick tests; HMW: high molecular weight; LMW: low molecular weight; 
SIC: specific inhalation challenge. 
*Atopy is defined as at least one positive reaction to skin prick tests to common allergens. 
 
 
 
OA 
N= 278 (27.5%) 
Non OA 
N= 734   (72.5%) 
P-value Total 
N= 1012 
Mean age at diagnosis, years (SD) 38.7 (10.7) 40.8 (10.9) 0.007 40.2 (10.9) 
Median exposure duration, years (min-
max) 
7.0 (0.0-48.0) 6.0 (0.0-54.0) 0.52 7.0 (0.0-54.0) 
Median delay between exposure 
cessation and testing, months (min-max) 
1.0 (0.0-127.0) 3.0 (0.0-69.0) 0.165 2.0 (0.0-127.0) 
Median symptoms duration, years (min-
max) 
2.0 (0.0-28.0) 1.0 (0.0-35.0) < 0.001 1.0 (0.0-35.0) 
Female, n (%) 82 (29.5) 278 (37.9) 0.013 360 (35.6) 
Smoking status, %   0.393  
- Never 113 (40.6) 278 (38.5)  391 (39.1) 
- Ex-smoker 97 (34.9) 237 (32.8)  334 (33.4) 
- Current smoker 68 (24.5) 208 (28.7)  276 (27.5) 
ICS use, n (%) 143 (51.4) 331 (45.2) 0.077 474 (46.9) 
Atopy#, n (%) 216 (81.2) 481 (70.4) 0.001 697 (73.4) 
Specific sensitization, n (%)   < 0.001  
- Positive SPT to occupational agent 129 (46.4) 72 (9.8)  201(19.9) 
- Negative SPT to occupational agent 15 (5.4) 92 (12.5)  107 (10.6) 
- SPT to occupational agent not done 134 (48.2) 570 (77.7)  704 (69.5) 
FEV1 < 80% pred, n (%) 59 (21.3) 143 (19.5) 0.519 202 (20.0) 
FEV1/FVC < 70%, n (%) 65 (24.2) 125 (17.1) 0.012 190 (19.0) 
Baseline PC20 < 16mg/ml, n (%) 223 (80.2) 388 (52.9) < 0.001 611 (60.4) 
Professional rhinitis, n (%) 74 (26.6) 89 (12.1) < 0.001 163 (16.1) 
Responsible agent, n (%)   < 0.001  
- HMW 142 (51.1) 163 (22.4)  305 (30.3) 
-- Flour 70 (25.2) 35 (4.8)  105 (10.4) 
-- Cereals 8 (2.9) 8 (1.1)  16 (1.6) 
-- Various proteins 15 (5.4) 47 (6.4)  62 (6.1) 
- LMW 133 (47.8) 549 (75.3)  682 (67.7) 
-- Isocyanates 68 (24.5) 135 (18.4)  203 (20.1) 
-- Chemicals 13 (4.7) 166 (22.6)  179 (17.7) 
-- Wood dust 16 (5.8) 35 (4.8)  51 (5.0) 
-- Metals 6 (2.2) 40 (5.4)  46 (4.5) 
-- Resins 18 (6.5) 55 (7.5)  73 (7.2) 
-Multiple 3 (1.1) 17 (2.3)  20 (2.0) 
Final diagnosis, n (%)   -  
- OA - -  278 (27.5) 
- Personal asthma  - -  376 (37.2) 
- Non-asthma  - -  358 (35.3) 
Type of reaction during SIC, n (%)   -  
- Immediate 164 (59.0) -  164 (16.2) 
- Late 58 (20.9) -  58 (5.7) 
- Dual 45 (16.2) -  45 (4.5) 
- Atypical 11 (3.9) -  11 (1.1) 
- No reaction 0 734 (100.0)  734 (72.5) 
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Table 2. Sensitivity, specificity, and positive and negative predictive values of the 
methacholine challenge  
 
 
   PC20 ≤ 16 
mg/ml 
PC20 > 16 
mg/ml  
Total  
PC20 at baseline (control day) (n=1012) 
OA 
Non OA 
223 
388  
55 
346 
278 
734  
Sensitivity 
Specificity 
0.802 
0.471 
PPV 
NPV 
0.365 
0.863 
PC20 at baseline AND at work (n=430) 
OA 
Non OA  
125 
179 
6 
120 
131 
299 
Sensitivity 
Specificity 
0.954 
0.401 
PPV 
NPV 
0.411 
0.952 
PC20 at baseline AND off work (n=582) 
OA 
Non OA 
98 
209 
49 
226 
147 
435 
Sensitivity 
Specificity  
0.667 
0.520 
PPV 
NPV 
0.319 
0.822 
PC20 measured at least once while at work (n=479) 
OA 
Non OA 
154 
196 
3 
126 
157 
322 
Sensitivity 
Specificity  
0.981 
0.391 
PPV 
NPV 
0.440 
0.977  
 
 
OA: occupational asthma; PPV: positive predictive value; NPV: negative predictive value
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Table 3. Multivariable model for the presence of non-specific bronchial responsiveness 
at baseline in the 278 cases of occupational asthma 
 
 β P-value OR (95% CI) 
Age > 40 years 0.184 0.768 0.9 (0.4-2.1) 
 
 
Female 0.464 
 
0.365 
 
 
1.6 (0.6-4.3) 
Smoking status 0.172 0.439 1.2 (0.8-1.8) 
Atopy 0.094 0.857 1.1 (0.4-3.1) 
 
 
ICS use 1.0 
 
 
0.012 
 
 
2.7 (1.2-5.9) 
FEV1 (L) -0.571 0.04 0.6 (0.3-1.0) 
 
 
FEV1/FVC < 70% -1.621 
 
 
0.044 
 
 
0.2 (0.0-1.0) 
Exposure duration > 7 years 0.228 0.6 1.3 (0.5-2.9) 
Symptom duration > 1 year 0.223 0.578 1.3 (0.6-2.7) 
HMW agent exposure -0.214 0.569 0.8 (0.4-1.7) 
 
 
At work during baseline challenge 1.827 
 
 
<0.001 
 
 
6.2 (2.7-14.4) 
 
ICS: inhaled corticosteroids; HMW: high molecular weight; OR: odds ratio; CI: 
confidence interval 
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Table 4. Subjects with occupational asthma, with and without baseline and post-specific 
inhalation challenge bronchial hyperresponsiveness 
 
 
SIC: specific inhalation challenge; OA: occupational asthma; ICS: inhaled corticosteroids; HMW: 
high molecular weight; LMW: low molecular weight; SD: standard deviation 
*Atopy is defined as at least one positive reaction to skin prick tests to common allergens. 
 
 
 
Baseline and post-SIC PC20 
> 16 mg/ml  
N=23 (8.3 %) 
Baseline and/or post-
SIC PC20 < 16 mg/ml  
N= 255 (91.7 %)  
P-value 
Mean age, years (SD) 37.1 (8.1) 38.8 (10.9) 0.458 
Median exposure duration, 
years (min-max) 
8.0 (0.0-26.0) 7.0 (0.0-48.0) 0.395 
Median delay between 
cessation of exposure and 
testing, months (min-max) 
4.0 (0.0-11.0) 0.0 (0.0-127.0) 0.854 
Median symptoms duration, 
years (min-max) 
2.0 (0.0-10.0) 2.0 (0.0-28.0) 0.274 
Female, n (%) 7 (30.4) 75 (29.4) 0.918 
Smoking status, n (%)     0.590 
- Never 9 (39.1) 104 (40.8)  
- Ex-smoker 10 (43.5) 87 (34.1)  
- Current smoker 4 (17.4) 64 (25.1)  
ICS use, n (%) 6 (26.1) 137 (53.7) 0.011 
Atopy*, n (%) 21 (95.5) 195 (79.9) 0.074 
FEV1 < 80% pred, n (%) 0 (0) 59 (23.2) 0.009 
FEV1/FVC < 70%, n (%) 1 (4.3) 64 (26.0) 0.020 
Professional rhinitis, n (%) 6 (26.1) 68 (26.7) 0.952 
Agents, n (%)      
- HMW 15 (65.2) 127 (49.8) 0.080 
- LMW 7 (30.4) 126 (49.4)  
- Multiple 1 (4.3) 2 (0.8)  
Type of asthmatic reaction, 
n (%) 
    0.170 
-Immediate 17 (73.9) 147 (57.7)  
-Late 5 (21.7) 53 (20.8)  
-Dual 0 (0) 45 (17.6)  
-Atypical 1 (4.3) 10 (3.9)  
Per-SIC PC20 decrease > 3.2 6 (26.1) 97 (38.0) 0.256 
Exposed at work during 
baseline SIC, n (%) 
0 (0.0) 133 (52.2) < 0.001 
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